Drug intelligence / Profile preview

casein glycomacropeptide protein substitute

Development stage
Unknown
Lead developer
Cambrooke Therapeutics
Modality
Recombinant Proteins and Enzymes
Administration
Oral
01

Overview

Casein glycomacropeptide protein substitute is a medical food formulated as a protein replacement for individuals with phenylketonuria (PKU), an inherited metabolic disorder requiring strict dietary phenylalanine restriction[1][4][5]. **CGMP** is a peptide derived from kappa-casein during cheese production; it is naturally low in phenylalanine but deficient in several essential amino acids (histidine, leucine, methionine, tryptophan, tyrosine) and therefore must be supplemented accordingly for complete nutritional adequacy[1][4]. CGMP-based substitutes offer an alternative to synthetic free amino acid (L-AA) protein substitutes, with potential advantages including improved palatability and possible metabolic benefits such as slower amino acid absorption and improved nitrogen retention[1][5]. Products are typically further fortified with vitamins, minerals, and sometimes other nutrients.

Brand names
PKU spherePhenylAde GMPGlytactinother GMP-based PKU medical foods
Other names
casein glycopeptidecasein macropeptideglycomacropeptidekappa-casein glycomacrompeptidecaseinoglycomacrompeptide
02

Targets

SLC7A5 (Large neutral amino acid transporter small subunit 1)

Beyond the preview

Go deeper on casein glycomacropeptide protein substitute.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on casein glycomacropeptide protein substitute.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call